Department of Medical Oncology, The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, 266061, China.
Cancer Institute, Qingdao, 266061, China.
Eur J Clin Microbiol Infect Dis. 2018 Dec;37(12):2235-2240. doi: 10.1007/s10096-018-3374-8. Epub 2018 Sep 12.
Cancer immunotherapy has been significantly effective on multiple cancers; however, there are still a distinct number of non-responding patients and various immune-related adverse events in responding patients. It is known that heterogeneity of intestinal microbiota may lead to different outcomes of therapy. Previous studies have reported that intestinal microbiota is probably attributed to influence the efficacy of cancer immunotherapy. Some intestinal bacteria could synergize with immune checkpoint blockade agents and optimize the immune response against multiple cancers. Therefore, understanding the roles of intestinal microbiota could help to improve the clinical efficacy of cancer immunotherapy. In this review, we first introduced the close relationships between intestinal microbiota and intestinal immune system. Then, we described the emerging evidences that intestinal microbiota responses to cancer immunotherapy. Finally, we briefly reviewed the technical development on intestinal microbiota research.
癌症免疫疗法在多种癌症中已取得显著疗效;然而,仍有相当数量的患者无应答,且应答患者存在各种免疫相关不良反应。已知肠道微生物组的异质性可能导致治疗结果不同。先前的研究表明,肠道微生物组可能影响癌症免疫疗法的疗效。一些肠道细菌可以与免疫检查点阻断剂协同作用,优化对多种癌症的免疫反应。因此,了解肠道微生物组的作用有助于提高癌症免疫疗法的临床疗效。在这篇综述中,我们首先介绍了肠道微生物组与肠道免疫系统之间的密切关系。然后,我们描述了肠道微生物组对癌症免疫疗法反应的新证据。最后,我们简要回顾了肠道微生物组研究的技术进展。